Cargando…

Targeted Therapy for Relapsed/Refractory Follicular Lymphoma: Focus on Clinical Utility of Tazemetostat

The management of follicular lymphoma (FL) in the relapsed and refractory setting is challenging and an area of ongoing investigation. Epigenetic dysregulation has recently been shown to be a hallmark of FL. Mutations in histone-modifying genes are likely early, driver events in FL pathogenesis, and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Raychaudhuri, Ruben, Ujjani, Chaitra
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8893153/ https://www.ncbi.nlm.nih.gov/pubmed/35250278 http://dx.doi.org/10.2147/OTT.S267011

Ejemplares similares

The role of tazemetostat in relapsed/refractory follicular lymphoma
por: von Keudell, Gottfried, et al.
Publicado: (2021)

The clinical development of obinutuzumab for the treatment of follicular lymphoma
por: Ma, Barbara, et al.
Publicado: (2017)

Phase 1 study of tazemetostat in Japanese patients with relapsed or refractory B‐cell lymphoma
por: Munakata, Wataru, et al.
Publicado: (2021)

Tazemetostat in relapsed/refractory follicular lymphoma: a propensity score–matched analysis of E7438-G000-101 trial outcomes
por: Proudman, David G., et al.
Publicado: (2022)

Targeted Treatment of Relapsed or Refractory Follicular Lymphoma: Focus on the Therapeutic Potential of Mosunetuzumab
por: Lopedote, Paolo, et al.
Publicado: (2023)

Phase II study of tazemetostat for relapsed or refractory B‐cell non‐Hodgkin lymphoma with EZH2 mutation in Japan
por: Izutsu, Koji, et al.
Publicado: (2021)

Recent Advances in the Management of Patients with Relapsed/Refractory Follicular Lymphoma
por: Pongas, Georgios, et al.
Publicado: (2021)

Copanlisib in the Treatment of Relapsed Follicular Lymphoma: Utility and Experience from the Clinic
por: Chauhan, Ayushi F, et al.
Publicado: (2021)

Systematic review of therapy used in relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma
por: Galaznik, Aaron, et al.
Publicado: (2018)

Treatment selection for patients with relapsed or refractory follicular lymphoma
por: Skarbnik, Alan Z., et al.
Publicado: (2023)

Tazemetostat: EZH2 Inhibitor
por: Straining, Rachael, et al.
Publicado: (2022)

Early clinical and metabolic response to tazemetostat in advanced relapsed INI1 negative epithelioid sarcoma
por: Tansir, Ghazal, et al.
Publicado: (2021)

Concurrent Diagnosis of Chronic Myeloid Leukemia and Follicular Lymphoma: An Unreported Presentation
por: Starr, Amy G., et al.
Publicado: (2018)

Primary effusion lymphoma: current perspectives
por: Narkhede, Mayur, et al.
Publicado: (2018)

Spotlight on copanlisib and its potential in the treatment of relapsed/refractory follicular lymphoma: evidence to date
por: Mensah, Felix A, et al.
Publicado: (2018)

Management of relapsed/refractory marginal zone lymphoma: focus on ibrutinib
por: Denlinger, Nathan M, et al.
Publicado: (2018)

Balancing considerations and qualifying conclusions for cost-effectiveness of therapies for relapsed/refractory follicular lymphoma
por: Potnis, Kunal C., et al.
Publicado: (2023)

P1109: TRIAL IN PROGRESS: PHASE 1B/2 TRIAL OF TAZEMETOSTAT IN COMBINATION WITH VARIOUS TREATMENTS IN PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES
por: Bessudo, A., et al.
Publicado: (2022)

Safety and activity of pembrolizumab in combination with rituximab in relapsed or refractory follicular lymphoma
por: Nastoupil, Loretta J., et al.
Publicado: (2022)

The Evolving Role of Brentuximab Vedotin in Classical Hodgkin Lymphoma
por: Lai, Catherine, et al.
Publicado: (2019)

Cost-effectiveness of chimeric antigen receptor T-cell therapy in adults with relapsed or refractory follicular lymphoma
por: Potnis, Kunal C., et al.
Publicado: (2022)

Emerging Pharmacotherapy for Relapsed or Refractory Hodgkin’s Lymphoma: Focus on Brentuximab Vedotin
por: Furtado, Michelle, et al.
Publicado: (2012)

Rituximab maintenance in relapsed or refractory follicular non-Hodgkin’s lymphoma: the evidence of its therapeutic value
por: Ardeshna, Kirit M.
Publicado: (2007)

Clinical significance of the loss of CD20 antigen on tumor cells in patients with relapsed or refractory follicular lymphoma
por: Michot, Jean-Marie, et al.
Publicado: (2021)

Efficacy comparison of tisagenlecleucel vs usual care in patients with relapsed or refractory follicular lymphoma
por: Salles, Gilles, et al.
Publicado: (2022)

S223: REAL-WORLD EARLY OUTCOMES OF AXICABTAGENE CILOLEUCEL FOR RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA
por: Jacobson, Caron, et al.
Publicado: (2023)

ATRT-17. TARGETING GLUTAMINE METABOLISM LOWERS METHYLATION POTENCIALS IN AT/RT AND SYNERGIZE WITH TAZEMETOSTAT
por: Nakata, Satoshi, et al.
Publicado: (2020)

A Matching-Adjusted Indirect Comparison of Single-Arm Trials in Patients with Relapsed or Refractory Follicular Lymphoma Who Received at Least Two Prior Systemic Treatments: Tazemetostat was Associated with a Lower Risk for Safety Outcomes Versus the PI3-Kinase Inhibitors Idelalisib, Duvelisib, Copanlisib, and Umbralisib
por: Proudman, David, et al.
Publicado: (2022)

Advances in the pathophysiology and treatment of relapsed/refractory Hodgkin’s lymphoma with an emphasis on targeted therapies and transplantation strategies
por: Karantanos, Theodoros, et al.
Publicado: (2017)

Comparative analysis of targeted novel therapies in relapsed, refractory chronic lymphocytic leukemia
por: Eyre, Toby A., et al.
Publicado: (2020)

P1111: COMPARATIVE EFFICACY AND SAFETY OF TISAGENLECLEUCEL AND AXICABTAGENE CILOLEUCEL IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA
por: Dickinson, M., et al.
Publicado: (2022)

Safety and efficacy of atezolizumab with obinutuzumab and bendamustine in previously untreated follicular lymphoma
por: Younes, Anas, et al.
Publicado: (2022)

Novel Therapies for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
por: Harris, Leonard Jeff, et al.
Publicado: (2020)

The Emerging Role of CAR T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma
por: Meier, Jeremy A., et al.
Publicado: (2022)

Brentuximab vedotin for relapsed or refractory Hodgkin’s lymphoma
por: Chen, Runzhe, et al.
Publicado: (2015)

Clinical Options in Relapsed or Refractory Hodgkin Lymphoma: An Updated Review
por: Fedele, Roberta, et al.
Publicado: (2015)

Safety and activity of ibrutinib in combination with durvalumab in patients with relapsed or refractory follicular lymphoma or diffuse large B‐cell lymphoma
por: Herrera, Alex F., et al.
Publicado: (2019)

Targeted Treatment of Follicular Lymphoma
por: Nath, Karthik, et al.
Publicado: (2021)

Evaluation of Tazemetostat as a Therapeutically Relevant Substance in Biliary Tract Cancer
por: Bekric, Dino, et al.
Publicado: (2023)

Clinical outcomes in patients relapsed/refractory after ≥2 prior lines of therapy for follicular lymphoma: a systematic literature review and meta-analysis
por: Kanters, Steve, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_334fq5d9tbm7duc5slm806b09t